Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00395941
Recruitment Status :
First Posted : November 6, 2006
Last Update Posted : March 20, 2019
Postgraduate Institute of Medical Education and Research
Information provided by (Responsible Party):
SHotra, Postgraduate Institute of Medical Education and Research
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with chronic plaque type psoriasis having body surface area involvement of > 20%
Patients of either sex
Females who have completed their family and are tubectomized or are postmenopausal i.e. no menstrual bleeding over at least 1 year
Age range 18-65 years
Females of child bearing potential
H/O hypersensitivity to acitretin
Impaired hepatic function (serum bilirubin, AST, ALT and alkaline phosphatase >1.5 times the upper limit of normal)
Impaired renal function (serum creatinine >1.5mg% in males and >1.4 mg% in females)